2-Methoxyethanol;2-propan-2-yloxypropane

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Methoxyethanol;2-propan-2-yloxypropane
• 英文别名: 2-methoxyethanol;2-propan-2-yloxypropane
• 化学式: C9H22O3
• 分子量: 178.27
• InChiKey: XJZJPFUOJWLKOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.44
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• CRYSTALLINE FORMS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4,4-DIMETHYLPENT-2-ENENITRILE
  申请人：Principia Biopharma Inc.

  公开号：US20210206772A1

  公开（公告）日：2021-07-08

  Crystalline forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of inhibiting BTK using the same, and methods for making crystalline forms of Compound (I) are also disclosed.
• TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4,4-DIMETHYLPENT-2-ENENITRILE
  申请人：Principia Biopharma Inc.

  公开号：US20210205313A1

  公开（公告）日：2021-07-08

  Disclosed herein are topical pharmaceutical compositions, e.g., for application to the skin of a subject, comprising (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile (Compound (I)), methods of making the same, and methods of using the same, e.g., for the treatment of various dermatological disorders.
• [EN] ACH-0142684 SODIUM SALT POLYMORPHS, COMPOSITION INCLUDING THE SAME, AND METHOD OF MANUFACTURE THEREOF<br/>[FR] POLYMORPHES DE SEL DE SODIUM D'ACH-0142684, COMPOSITION LES COMPRENANT, ET LEUR PROCÉDÉ DE FABRICATION
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2014145600A1

  公开（公告）日：2014-09-18

  The disclosure provides a crystalline sodium salt of ACH-0142684 ACH-0142684 Sodium Salt comprising a Form A polymorph, a Form B polymorph, a Form C polymorph, a Form D polymorph, a Form E polymorph, a Form F polymorph, a Form G polymorph, a Form H polymorph, a Form I polymorph, or a combination thereof, wherein the Form A, B, C, D, E, F, G, H, and I polymorph exhibits an X-ray powder diffraction pattern having peak locations in accordance with Figs. 8; 12; 15; 21; 22; 27; 30, and 31, respectively.